Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 24, 2019
- Accepted in final form July 8, 2019
- First Published August 7, 2019.
Author Disclosures
- Alberto Vogrig, MD*,
- Marine Fouret, MD*,
- Bastien Joubert, MD,
- Géraldine Picard, MSc,
- Véronique Rogemond, PhD,
- Anne-Laurie Pinto, MSc,
- Sergio Muñiz‐Castrillo, MD,
- Maxime Roger, MD,
- Judith Raimbourg, MD, PhD,
- Charles Dayen, MD,
- Laurianne Grignou, MD,
- Maud Pallix-Guyot, MD,
- Julien Lannoy, MD,
- François Ducray, MD, PhD,
- Virginie Desestret, MD, PhD,
- Dimitri Psimaras, MD and
- Jérôme Honnorat, MD, PhD
- Alberto Vogrig, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marine Fouret, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bastien Joubert, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Academy of Neurology awarded the following grant: EAN Research Training Fellowship 2019
NONE
NONE
NONE
NONE
NONE
NONE
- Géraldine Picard, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Véronique Rogemond, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne-Laurie Pinto, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sergio Muñiz‐Castrillo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maxime Roger, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Judith Raimbourg, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Charles Dayen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laurianne Grignou, MD,
NONE
NONE
1) Train ticket and hotel for JNLF congress 2019, SANOFI Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maud Pallix-Guyot, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julien Lannoy, MD,
NONE
(1)Roche funding for travel AAN 2019 at Philadelphia (2)Sanofi Genzyme funding for travel ECTRIMS 2017 at Amsterdam
NONE
(1)Lettre du Neurologue e-journal ECTRIMS 2018, writer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- François Ducray, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Virginie Desestret, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dimitri Psimaras, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jérôme Honnorat, MD, PhD
Scientific advisory board for Bristol Meyers Squibb
NONE
NONE
NONE
receives royalties from licensing fees to AthenaDiagnostics, Euroimmun, and ravo Diagnostika for a patentfor the use of CV2/CRMP5 as diagnostic tests.
NONE
NONE
NONE
NONE
NONE
NONE
Research support from CSL Behring France
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Centre National de Référence pour les Syndromes Neurologiques Paranéoplasiques (A.V., M.F., B.J., G.P., V.R., A.-L.P., S.M.-C., F.D., V.D., J.H.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Lyon, France; University Claude Bernard Lyon 1, Université de Lyon; Service de Pneumologie-Oncologie Thoracique-Soins Intensifs Respiratoires (M.R.), Centre Hospitalier Universitaire de Rouen; Service d'Oncologie Médicale (J.R.), Institut de Cancérologie de l'Ouest René Gauducheau, St. Herblain; Service de Pneumologie (C.D.), Centre Hospitalier de Saint-Quentin; Service de Neurologie et Unité Neuro-Vasculaire—Hôpital de La Cavale Blanche (L.G.), Brest; Service de Neurologie et Unité Neurovasculaire (M.P.-G.), Centre Hospitalier Régional d'Orléans; Service de Neurologie—Pathologies Inflammatoires (J.L.), Centre Hospitalier Universitaire de Lille; and AP-HP (D.P.), Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin et Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975; Inserm U 975, CNRS, UMR 7225; Centre de Compétence des Syndromes Neurologiques Paraneoplasiques et Encéphalites Autoimmunes, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
- Correspondence
Dr. Honnorat jerome.honnorat{at}chu-lyon.fr
Article usage
Letters: Rapid online correspondence
- Author response: Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
- Alberto Vogrig, Neurologist, French refererence center on paraneoplastic neurological diseases and autoimmune encephalitis
- Marine Fouret, Neurologist, French refererence center on paraneoplastic neurological diseases and autoimmune encephalitis
- Sergio Muñiz-Castrillo, Neurologist, French refererence center on paraneoplastic neurological diseases and autoimmune encephalitis
- Jérôme Honnorat, Professor of Neurology, French refererence center on paraneoplastic neurological diseases and autoimmune encephalitis
Submitted September 14, 2019 - Reader response: Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
- Ahmed Z. Obeidat, Neurologist, Department of Neurology, Medical College of Wisconsin
Submitted September 07, 2019
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Neurologic autoimmunity and immune checkpoint inhibitorsAutoantibody profiles and outcomesElia Sechi, Svetomir N. Markovic, Andrew McKeon et al.Neurology, August 13, 2020 -
Article
Cranial Nerve Disorders Associated With Immune Checkpoint InhibitorsAlberto Vogrig, Sergio Muñiz-Castrillo, Bastien Joubert et al.Neurology, December 14, 2020 -
Article
Updated Diagnostic Criteria for Paraneoplastic Neurologic SyndromesFrancesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo et al.Neurology: Neuroimmunology & Neuroinflammation, May 18, 2021 -
Views & Reviews
Neurologic Adverse Events of Immune Checkpoint InhibitorsA Systematic ReviewAlessandro Marini, Andrea Bernardini, Gian Luigi Gigli et al.Neurology, March 02, 2021